Erratum: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial (Ann Oncol (2017) 28 (128–135) DOI:10.1093/annonc/mdw434);Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

Annals of Oncology

Volumn 28, Issue 1, 2017, Pages 128-135

  Shi, W ^a   Jiang, T ^a   Nuciforo, P ^b   Hatzis, C ^a   Holmes, E ^c   Harbeck, N ^d   Sotiriou, C ^e   Pena L ^f   Loi, S ^g   Rosa, D D ^h   Chia, S ⁱ   Wardley, A ^j   Ueno, T ^k   Rossari, J ^h   Eidtmann, H ^l   Armour, A ^m   Piccart Gebhart, M ^e   Rimm, D L ^a   Baselga, J ⁿ   Pusztai, L ^a  

^a YALE CANCER CENTER   (United States)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^d UNIVERSITY OF MUNICH   (Germany)

^e JULES BORDET INSTITUTE   (Belgium)

^f SOLTI Breast Cancer Research Group   (Spain)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h HOSPITAL MOINHOS DE VENTO   (Brazil)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^j CHRISTIE HOSPITAL   (United Kingdom)

^k KYOTO UNIVERSITY HOSPITAL   (Japan)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m Novartis   (United Kingdom)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Breast cancer NeoALTTO trial; PIK3CA related network; Regulation of RhoA activity; Whole exome sequencing

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RHOA PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; GENE MUTATION; HUMAN; HUMAN TISSUE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; WHOLE EXOME SEQUENCING; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; ENZYMOLOGY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENETICS; METABOLISM; MUTATION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DNA, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; RHOA GTP-BINDING PROTEIN; TRASTUZUMAB; WHOLE EXOME SEQUENCING;

EID: 85015720647     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx805     Document Type: Erratum

References (17)

1. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, openlabel, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
2. Majewski IJ, Nuciforo P, Mittempergher L et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 2015; 33(12): 1334-1339.
3. Salgado R, Denkert C, Campbell C et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in her2-positive early-stage breast cancer treated with lapatinib and trastuzumab A secondary analysis of the NeoALTTO Trial. JAMA Oncol 2015; 1(4): 448-455.
4. Loibl S, Von Minckwitz G, Schneeweiss A et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32(29): 3212-3220.
5. Perez EA, Thompson EA, Ballman KV et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial. J Clin Oncol 2015; 33: 701-708.
6. Carvajal-Hausdorf D., Schalper K., Pusztai L et al. Measurement of domain-specific HER2 (ERBB2) expression may classify benefit from trastuzumab in breast cancer. J Natl Cancer Inst 2015; 107(8): djv136. doi: 10.1093/jnci/djv136.
7. Scaltriti M, Nuciforo P, Bradbury I et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 2015; 21(3): 569-576.
8. Rimawi MF, Schiff R, Osborne KC. Targeting HER2 for the Treatment of Breast Cancer. Annual Rev Med 2015; 66: 111-128.
9. Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-15550.
10. Cancer Genome Atlas Research, Network. "The Cancer Genome Atlas Pan-Cancer analysis project." Nature Genet 2013; 45(10): 1113-1120.
11. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402.
12. Clark AS, West K, Streicher S et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1:707-717.
13. Kakiuchi M, Nishizawa T, Ueda H et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nature Genet 2014; 46(6): 583-587.
14. Simpson KJ, Dugan AS, Mercurio AM Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 2004; 64(23): 8694-8701.
15. Zaoui K, Benseddik K, Daou P et al. ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells. Proc Natl Acad Sci USA 2010; 107(43): 18517-18522.
16. Pillé JY, Denoyelle C, Varet J et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005; 11(2): 267-274.
17. Cao XX, Xu JD, Xu JW et al. RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat 2011; 126(3): 555-563.